Contineum Therapeutics, Inc. Class A Common Stock
CTNMNASDAQHealthcare● Active
$11.54
+$0.05(+0.44%)
Market Cap$431438756
P/E Ratio—
52W High$16.33
52W Low$3.57
Contineum Therapeutics, Inc. Class A Common Stock（CTNM）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · CTNM · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.05B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | ($0.00B) | $0.05B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | 100.00% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.05B | $0.04B | $0.03B | $0.02B | $0.02B |
| G&A Expenses | $0.02B | $0.01B | $0.01B | $0.01B | $0.01B |
| Total Operating Expenses | $0.07B | $0.05B | $0.07B | $0.02B | $0.03B |
| Operating Income | ($0.07B) | ($0.05B) | ($0.02B) | ($0.02B) | ($0.03B) |
| Operating Margin %(computed) | — | — | -32.15% | — | — |
| Interest Income | $0.01B | $0.01B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.06B) | ($0.04B) | $0.02B | ($0.02B) | ($0.03B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.06B) | ($0.04B) | $0.02B | ($0.02B) | ($0.03B) |
| Net Margin %(computed) | — | — | 45.44% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.17 | $-1.63 | $0.13 | $-0.97 | $-1.15 |
| Wtd Avg Shares | 0.03B | 0.03B | 0.03B | 0.03B | 0.03B |
| EBITDA | ($0.07B) | ($0.04B) | $0.02B | ($0.02B) | ($0.03B) |
| EBITDA Margin %(computed) | — | — | 47.15% | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · B
深入了解Contineum Therapeutics, Inc. Class A Common Stock
关于Contineum Therapeutics, Inc. Class A Common Stock（CTNM）损益表
Contineum Therapeutics, Inc. Class A Common Stock（CTNM）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，CTNM实现营收$0.00B，毛利润$0.00B（毛利率—），净利润($0.06B)（净利率—）。
常见问题
CTNM · 4 问Contineum Therapeutics, Inc. Class A Common Stock（CTNM）2025财年营收为$0.00B，同比down—%。
CTNM revenueCTNM salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08